Redeye leaves a more elaborate take on Genovis following its Q3 2022 report. We are left with a positive bias after yesterday's report and make minor adjustments to our forecasts, resulting in an updated fair value range.
ANNONS
Redeye leaves a more elaborate take on Genovis following its Q3 2022 report. We are left with a positive bias after yesterday's report and make minor adjustments to our forecasts, resulting in an updated fair value range.